CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a ...
Lupus Science & Medicine

Lectin pathway of complement in SLE: MAP-1 as a marker of haematological manifestations and elevated type I interferon activity

Objective SLE is a systemic autoimmune disease in which the complement system plays a key pathogenic role, yet the ...
Medical Xpress

Scientists pinpoint a skin alarm system pathway that links local damage to systemic immune responses

Skin, our largest organ, acts as a protective barrier against pathogens that try to invade our bodies while constantly monitoring for potential threats. In the skin's outermost layer, the epidermis, ...
Medical Xpress

Stress-activated pathway reveals how nervous system contributes to eczema flare-ups

The mystery of how stress exacerbates atopic dermatitis, more commonly known as eczema, may be closer to being understood. A new study published in the journal Science has identified a specific nerve ...
Healio

Age-Related Macular Degeneration

Photoreceptors are specialized neurons that convert light into electrical signals that are processed in the visual cortex to form images. The RPE is a cell layer that is adjacent to the photoreceptors ...
Medscape

Can Hope Prime the Immune System via Brain Reward Pathways?

A study published in Nature Medicine identified a link between the placebo effect and immune system function. In the experiment, individuals who generated positive expectations showed a stronger ...
Seeking Alpha

Omeros Announces First Commercial Sales of YARTEMLEA®

— Initial Orders Received and Fulfilled from Multiple Transplant Centers, with YARTEMLEA Now Administered to Both Adult and Pediatric Patients with TA-TMA — YARTEMLEA is the first and only approved ...
WebMD

FDA Approves Yartemlea, the First and Only Treatment for Transplant-Related Blood Vessel Damage

What Is Yartemlea, and Why Does It Matter? Yartemlea (narsoplimab-wuug) is a new medicine approved by the FDA for treating a rare and serious condition called transplant-associated thrombotic ...
MarketWatch

FDA Approves Omeros' YARTEMLEA(R) -- First and Only Therapy Indicated for TA-TMA

The MarketWatch News Department was not involved in the creation of this content. -- Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: ...
MarketWatch

Omeros Gets FDA Approval of Yartemlea

Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants. Omeros on Wednesday said the approval covers Yartemlea ...
Nasdaq

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of ...